ArticleGeroScience2025
Detecting early stages of Alzheimer's disease using a web-based cognitive battery.
Article in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Reliable detection and continuous monitoring of memory dysfunction in mild cognitive impairment and healthy aging through adaptive computational phenotyping.PLOS digital health · 2026Article
- Computer-Assisted Performance-Based Assessment for Mental Health: A Scoping Review.PsyCh journal · 2026Article
- Executive functions in adults: scoping review of computerized neuropsychological batteries.Dementia & neuropsychologia · 2026Review
- Web-based LAS-FNAME and blood biomarkers in autosomal dominant Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Portable and efficient cognitive screening measures are needed to address the growing need for effective early detection of Alzheimer's disease. The Neurotrack Cognitive Battery (NCB) offers an appealing, web-based application that may be sensitive to early cognitive changes associated with Alzheimer's disease. The NCB contains measures that were conceptually derived from animal lesion studies. The current study sought to investigate the construct and diagnostic validity of the NCB among those with and without mild cognitive impairment (MCI). Participants (n = 47) with and without MCI were administered the NCB and traditional cognitive tests. Three of six NCB measures assessing domains of memory, processing speed, and executive functioning demonstrated moderate to strong associations with well-established cognitive performance tests. In classifying those with and without MCI, sensitivities of these three NCB measures ranged from 0.47 to 0.74, and specificities ranged from 0.78 to 1.00. For traditional cognitive measures, sensitivities ranged from 0.74 to 0.84, and specificities ranged from 0.74 to 0.94. Overall, web-based cognitive test measures pertaining to cognitive domains of memory, processing speed, and executive functioning may serve as highly portable screening tools for detecting the early stages of Alzheimer's disease. Additionally, these cognitive domains may be valuable in informing back-translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.